Items Tagged ‘UNM CC Features’

March 2, 2011

Long-Term Bisphosphonate Use Linked with Unusual Femur Fractures

By

According to a study published in the Journal of the American Medical Association, long-term use of the osteoporosis drugs known as bisphosphonates may increase the risk of unusual types of femur fractures. The risk of these unusual fractures remains low, however, and should be balanced against the established benefits of bisphosphonates, which include a reduction […]

View full entry

Tags: UNM CC Features


February 22, 2011

Sutent and Afinitor Show Promise against Advanced Pancreatic Neuroendocrine Tumors

By

In two separate Phase III clinical trials, the targeted drugs Sutent® (sunitinib) and Afinitor® (everolimus) delayed the progression of advanced pancreatic neuroendocrine tumors. These results were published in the New England Journal of Medicine. Pancreatic neuroendocrine tumors are a relatively uncommon type of cancer that develops in the hormone-producing cells of the pancreas. Sutent is […]

View full entry

Tags: UNM CC Features


January 10, 2011

Weight Lifting May Not Increase Lymphedema Risk Among Breast Cancer Survivors

By

It may be safe for breast cancer survivors to lift weights, including upper-body exercises, without increasing risk for lymphedema. These results were reported in the Journal of the American Medical Association. Lymphedema refers to swelling of the arm due to an accumulation of lymph fluid. It commonly affects women who have had axillary (underarm) lymph […]

View full entry

Tags: UNM CC Features


January 10, 2011

Iniparib Shows Promise Against Triple-Negative Breast Cancer

By

Compared with chemotherapy alone, treatment with a combination of chemotherapy and the investigational drug iniparib improved overall survival by more than four months among women with metastatic, triple-negative breast cancer. The results of this Phase II clinical trial were published in the New England Journal of Medicine. Breast cancers that are estrogen receptor-negative, progesterone receptor-negative, […]

View full entry

Tags: UNM CC Features


December 20, 2010

Onco DX Influences Breast Cancer Treatment Decisions

By

The Oncotype DX® breast cancer test may change treatment decisions for more than a third of women with early, estrogen receptor-positive breast cancer. These results were presented at the 2010 San Antonio Breast Cancer Symposium. The Oncotype DX breast cancer test measures the expression of 21 genes in a sample of tumor tissue. The test […]

View full entry

Tags: UNM CC Features


October 28, 2010

Addition of Hycamtin Doesn’t Improve Outcomes in Newly Diagnosed Ovarian Cancer

By

Among women with newly diagnosed, advanced ovarian cancer, treatment with Hycamtin® (topotecan) and cisplatin prior to standard chemotherapy increases side effects and does not improve progression-free survival. These results were published in the Journal of the National Cancer Institute. Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading […]

View full entry

Tags: UNM CC Features


October 18, 2010

European Study Reports that Oncotype DX® Influences Breast Cancer Treatment Decisions

By

Consistent with what has been reported in the United States, use of the Oncotype DX® breast cancer test influenced treatment decisions for early-stage breast cancer patients in Spain. These results were presented at the 35th European Society for Medical Oncology (ESMO) Congress. The Oncotype DX breast cancer test measures the expression of 21 genes in […]

View full entry

Tags: UNM CC Features


October 13, 2010

Pregnancy Doesn’t Appear to Worsen Breast Cancer Outcomes

By

According to the results of a study conducted at the M. D. Anderson Cancer Center, women who are diagnosed with breast cancer and treated with chemotherapy while pregnant have better disease-free survival (survival without a cancer recurrence or a new cancer) than women who are not pregnant at the time of diagnosis. Overall survival was […]

View full entry

Tags: UNM CC Features


October 4, 2010

Higher Dose of Faslodex® More Effective for Advanced Breast Cancer

By

Among postmenopausal women with advanced, estrogen receptor-positive breast cancer that has progressed or recurred after prior hormonal therapy, a 500 mg dose of Faslodex® (fulvestrant) appears to be more effective than the originally approved 250 mg dose. These results were published in the Journal of Clinical Oncology. As a result of these findings, the 500 […]

View full entry

Tags: UNM CC Features


September 22, 2010

Multivitamins Don’t Improve Colon Cancer Outcomes

By

In a study of patients with Stage III colon cancer, use of multivitamins during and after chemotherapy did not improve survival or reduce the risk of recurrence. These results were published in the Journal of Clinical Oncology. Stage III colon cancer refers to cancer that has spread to lymph nodes surrounding the colon but not […]

View full entry

Tags: UNM CC Features


August 27, 2010

Reduced-intensity Treatment May be Effective for Early Hodgkin’s Lymphoma

By

Among patients with early-stage Hodgkin’s lymphoma and a favorable prognosis, it may be possible to reduce the number of chemotherapy cycles and the dose of radiation therapy without adversely affecting outcome. The results of this study were published in the New England Journal of Medicine. Hodgkin’s lymphoma is a cancer of the lymph system and […]

View full entry

Tags: UNM CC Features


August 17, 2010

Hepatitis B Virus Linked with Non-Hodgkin’s Lymphoma

By

Individuals with chronic hepatitis B virus (HBV) infection may have an increased risk of developing non-Hodgkin’s lymphoma (NHL), according to findings recently published in The Lancet Oncology. Hepatitis B is a virus that causes inflammation of the liver. It is spread through contact with body fluids and can be transmitted through blood, sexual contact, or […]

View full entry

Tags: UNM CC Features


August 11, 2010

Provenge® for Hormone-refractory Prostate Cancer

By

Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine.[1] The prostate is a male sex gland responsible for producing fluid that forms semen. It is located below the bladder, […]

View full entry

Tags: UNM CC Features


August 3, 2010

Study Evaluates Safety of Avastin and Chemotherapy in Non–Squamous Non–Small Cell Lung Cancer

By

A large Phase IV study confirms that the safety and efficacy reported in Phase III trials of Avastin® (bevacizumab) plus standard chemotherapy for patients with advanced non-squamous non-small cell lung cancer translate into the clinical practice setting. These findings were recently published in the journal The Lancet Oncology.[1] Lung cancer is the leading cause of […]

View full entry

Tags: UNM CC Features


July 23, 2010

Higher Cancer Rates Among Children Conceived with IVF

By

Children conceived using in vitro fertilization (IVF) may have a higher risk of cancer compared with children born without IVF, according to a study published in Pediatrics. In vitro fertilization is a type of assisted reproductive technology that is used when parents cannot conceive a child on their own. In IVF, the egg cells are […]

View full entry

Tags: UNM CC Features